Stockholm, 01 June 2022 – Today, Kebni announces a new 1.05 MSEK order for the inertial sensing multisensor platform SensAItion. The SensAItion development kit that was ordered and delivered in January has been reviewed by the end-user. The undisclosed end-user, a top-tier Fortune 500 corporation, now proceeds with an additional purchase of 100+ SensAItion IMU units.

“We are now redesigning our end-user solution in favour of Kebni’s SensAItion, replacing the currently used product. Compliance with the increasingly important ISO26262-standard that safeguards functional safety of electronic systems for road vehicles is an extra benefit.” – Prevas Development, System Integration Partner

This order confirms that the test phase, which validated technical compliance and performance, is finalized and that the end-user proceeds with Kebni’s product for operational use. The deliveries are scheduled for 2022.

“This is a fantastic breakthrough-order for Kebni, recognizing and confirming that we develop competitive products which provide genuine value for global clients.” – Torbjörn Saxmo, CEO

“The message couldn’t be clearer: Kebni is on the right track and moving fast. And for the inertial sensing platform SensAItion, it’s a sensation.” – Erik Winther, Head of Sales

Ämnen i artikeln


KebNi B

Senast

1,81

1 dag %

−0,77%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

−0,01%

Senast

2 448,97

1 mån
Loading market data...
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Palutko Macéus
Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.
Affärsvärlden
AFV
Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.
Annons
Introduce
för börsens små- och medelstora företag.
Annons
Investtech
Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.